pirfenidone has been researched along with Diabetic Nephropathies in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, Z; Cheng, Z; Hu, G; Jiang, D; Li, Q; Lu, M; Peng, Z; Tao, L; Xiong, X | 1 |
| Alicic, RZ; Tuttle, KR | 1 |
| Cazenave, M; Gauthier, M; Gueutin, V; Izzedine, H | 1 |
| Dunn, SR; McGowan, TA; Okada, S; RamachandraRao, SP; Ravasi, T; Sharma, K; Shaw, MA; Toh, I; Zhu, Y | 1 |
| Declèves, AE; Sharma, K | 1 |
| Cho, M; Donohue, M; Dunn, SR; Falkner, B; Fervenza, FC; Francos, B; Ix, JH; Kopp, JB; Mathew, AV; McGowan, TA; Pflueger, A; Ramachandrarao, S; Sharma, K; Sharma, S; Xu, R | 1 |
| Beaulieu, MC; Levin, A | 1 |
| McGowan, TA; Sharma, K; Zhu, Y | 1 |
4 review(s) available for pirfenidone and Diabetic Nephropathies
| Article | Year |
|---|---|
Novel therapies for diabetic kidney disease.
Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antioxidants; Bosentan; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelins; Enzyme Inhibitors; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Indoles; Janus Kinases; Maleimides; Polyamines; Protein Kinase C; Pyridones; Pyridoxamine; Sevelamer; Sulfonamides | 2014 |
[Diabetic nephropathy: emerging treatments].
Topics: Adrenocorticotropic Hormone; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antifibrinolytic Agents; Antineoplastic Agents, Hormonal; Antioxidants; Bone Density Conservation Agents; Diabetic Nephropathies; Doxycycline; Enzyme Inhibitors; Ergocalciferols; Hormones; Humans; Indoles; Maleimides; Octreotide; Pentoxifylline; Pyridones; Pyridoxamine; Silymarin; Vitamin B Complex | 2014 |
New pharmacological treatments for improving renal outcomes in diabetes.
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biomarkers; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Protein Kinase C; Pyridones; Renin; Transforming Growth Factor beta | 2010 |
Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropathies; Disease Models, Animal; Humans; Kidney Failure, Chronic; Pyridones; Transforming Growth Factor beta | 2004 |
1 trial(s) available for pirfenidone and Diabetic Nephropathies
| Article | Year |
|---|---|
Pirfenidone for diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Creatinine; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrosis; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Pyridones; Treatment Outcome | 2011 |
3 other study(ies) available for pirfenidone and Diabetic Nephropathies
| Article | Year |
|---|---|
Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Discovery; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Mice; Molecular Structure; NIH 3T3 Cells; Oxidative Stress; Piperazines; Pyridones; Rats; Structure-Activity Relationship | 2018 |
Pirfenidone is renoprotective in diabetic kidney disease.
Topics: Albuminuria; Animals; Antineoplastic Agents; Cell Line; Diabetic Nephropathies; Eukaryotic Initiation Factor-4E; Extracellular Matrix Proteins; Gene Expression; Humans; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; Phosphorylation; Proteomics; Pyridones; Reactive Oxygen Species; RNA Processing, Post-Transcriptional; Signal Transduction; Transforming Growth Factor beta1 | 2009 |
Trials and tribulations of new agents, novel biomarkers, and retarding renal progression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Kidney; Pyridones; Transforming Growth Factor beta | 2011 |